Sabin IPV + Sabin IPV + bOPV — Competitive Intelligence Brief

Sabin IPV + Sabin IPV + bOPV (Sabin IPV + Sabin IPV + bOPV) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: vaccine. Area: Immunology / Infectious Disease.

marketed vaccine Immunology / Infectious Disease Biologic

Target snapshot

Sabin IPV + Sabin IPV + bOPV (Sabin IPV + Sabin IPV + bOPV) — Zhejiang Provincial Center for Disease Control and Prevention. This is a combination polio vaccine containing inactivated poliovirus vaccine (IPV) derived from Sabin strains plus bivalent oral polio vaccine (bOPV) to provide immunization against poliovirus types 1, 2, and 3.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sabin IPV + Sabin IPV + bOPV TARGET	Sabin IPV + Sabin IPV + bOPV	Zhejiang Provincial Center for Disease Control and Prevention	marketed	vaccine
Comirnaty	BNT162b2 (tozinameran)	Pfizer Inc.	marketed	vaccine	SARS-CoV-2 virus	2021-08-23
Prevnar 20	pneumococcal 20-valent conjugate vaccine (PCV20)	Pfizer Inc.	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (20 serotypes)	2021-06-08
Sabin IPV	Sabin IPV	Centers for Disease Control and Prevention, China	marketed	inactivated viral vaccine	poliovirus serotypes 1, 2, and 3
Spikevax Omicron XBB.1.5	Spikevax Omicron XBB.1.5	Jules Bordet Institute	marketed	mRNA vaccine	SARS-CoV-2 spike protein (XBB.1.5 variant)
hepatitis A vaccine, DTaP, PCV10	hepatitis A vaccine, DTaP, PCV10	KEMRI-Wellcome Trust Collaborative Research Program	marketed	combination vaccine
H5N1 vaccine (Arepanrix)	H5N1 vaccine (Arepanrix)	Canadian Immunization Research Network	marketed	inactivated split-virion influenza vaccine with adjuvant

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2033-06-01 — Prevnar 20 · US 8,895,024 · Composition of matter · US
• 2035-06-01 — Prevnar 20 · US 10,279,033 · Method of use · US

Sponsor landscape (vaccine class)

1. Pfizer · 20 drugs in this class
2. Sanofi Pasteur, a Sanofi Company · 20 drugs in this class
3. GlaxoSmithKline · 12 drugs in this class
4. Merck Sharp & Dohme LLC · 12 drugs in this class
5. Centers for Disease Control and Prevention · 9 drugs in this class
6. Zhejiang Provincial Center for Disease Control and Prevention · 7 drugs in this class
7. Jiangsu Province Centers for Disease Control and Prevention · 6 drugs in this class
8. Beijing Center for Disease Control and Prevention · 6 drugs in this class
9. International Centre for Diarrhoeal Disease Research, Bangladesh · 5 drugs in this class
10. Sinovac Biotech Co., Ltd · 4 drugs in this class